An observational study in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Nasal Polyps, sponsored by Harran University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Harran University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory disease of the sinonasal mucosa whose metabolic and immunologic mechanisms are incompletely understood. This prospective case-control study aims to characterize metabolic and immunologic biomarkers in patients with CRSwNP compared with control subjects. Nasal tissue and peripheral blood samples will be analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) for free amino acid and carnitine/acylcarnitine profiles, and levels of interleukin-40 (IL-40), interleukin-6 (IL-6), and hypoxia-inducible factor-1 alpha (HIF-1α) will be measured by ELISA. The findings are expected to contribute to understanding disease pathogenesis and to identifying potential diagnostic biomarkers and therapeutic targets.
Adult patients presenting to the Otorhinolaryngology outpatient clinic of Harran University Faculty of Medicine with nasal obstruction and a histopathologically confirmed diagnosis of nasal polyposis (by punch biopsy or surgical specimen) will be enrolled. Nasal polyp tissue and peripheral blood samples will be collected from 40 patients with CRSwNP. The control group will consist of 40 patients undergoing septoplasty, rhinoplasty or similar nasal surgery for reasons other than nasal polyps, from whom healthy nasal mucosa biopsies and peripheral blood samples will be obtained. Free amino acid and carnitine/acylcarnitine profiles will be determined in tissue and serum by LC-MS/MS, and IL-40, IL-6 and HIF-1α concentrations will be measured by ELISA. Metabolic and immunologic differences between nasal polyp tissue and healthy nasal mucosa, and their reflection in peripheral blood, will be compared between groups. Tissue and blood levels obtained from the same individual will be compared using paired tests, and correlations between metabolic parameters and immune markers will be assessed by Pearson or Spearman correlation analysis. In the CRSwNP group, associations of these biomarkers with disease severity, symptom scores and endoscopic findings will also be evaluated. The diagnostic performance of candidate biomarkers will be assessed by receiver operating characteristic (ROC) analysis. To our knowledge, IL-40 has not previously been investigated in CRSwNP.
236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.
This study's planned enrollment of 80 is below the median of 100 across 47 observational studies indexed under Nasal Polyps.
Browse Nasal Polyps studies →Harran University is the lead sponsor of 64 studies on the registry; 21 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients presenting with nasal obstruction to the Otorhinolaryngology outpatient clinic of Harran University Faculty of Medicine, Şanlıurfa, Turkey, with histopathologically confirmed chronic rhinosinusitis with nasal polyps (by punch biopsy or surgical specimen), and adult control patients without chronic rhinosinusitis scheduled for septoplasty, rhinoplasty or similar nasal surgery at the same department.
CRSwNP Group
Inclusion Criteria:
Exclusion Criteria:
Control Group
Inclusion Criteria:
Exclusion Criteria:
* Same exclusion criteria as the CRSwNP group
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients diagnosed with chronic rhinosinusitis with nasal polyps according to EPOS 2020 criteria, with nasal polyposis confirmed histopathologically by punch biopsy or surgical specimen. Nasal polyp tissue is obtained by punch biopsy in the outpatient clinic or during endoscopic sinus surgery, and a peripheral venous blood sample is collected at the same time. No additional intervention is applied.
Other: Nasal polyp tissue and blood sampling
Adult patients without nasal polyposis or chronic rhinosinusitis scheduled for septoplasty, rhinoplasty or similar nasal surgery for reasons other than nasal polyps. A healthy nasal mucosa biopsy is obtained during surgery, and a peripheral venous blood sample is collected at the same time. No additional intervention is applied.
Other: Nasal mucosa and blood sampling
Nasal polyp tissue is obtained by punch biopsy in the outpatient clinic or during endoscopic sinus surgery, and a peripheral venous blood sample is collected at the same time. No additional intervention is applied.
A healthy nasal mucosa biopsy is obtained during septoplasty, rhinoplasty or similar nasal surgery, and a peripheral venous blood sample is collected at the same time. No additional intervention is applied.
Tissue and serum free amino acid and carnitine/acylcarnitine profiles
Concentrations of free amino acids, free carnitine and acylcarnitines measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in nasal tissue and serum, compared between the CRSwNP and control groups.
Time frame: At the time of tissue sampling (Day 0)
Interleukin-40 (IL-40) levels in tissue and serum
IL-40 concentrations measured by ELISA in nasal tissue and serum, compared between the CRSwNP and control groups.
Time frame: At the time of tissue sampling (Day 0)
Interleukin-6 (IL-6) levels in tissue and serum
IL-6 concentrations measured by ELISA in nasal tissue and serum, compared between the CRSwNP and control groups.
Time frame: At the time of tissue sampling (Day 0)
Hypoxia-inducible factor-1 alpha (HIF-1α) levels in tissue and serum
HIF-1α concentrations measured by ELISA in nasal tissue and serum, compared between the CRSwNP and control groups.
Time frame: At the time of tissue sampling (Day 0)
Diagnostic performance of candidate biomarkers
Area under the receiver operating characteristic curve (AUC), sensitivity and specificity of tissue and serum amino acid, carnitine/acylcarnitine, IL-40, IL-6 and HIF-1α levels for discriminating CRSwNP from control subjects.
Time frame: At the time of tissue sampling (Day 0)
Plan to share: No — Individual participant data will not be shared in order to protect participant confidentiality in accordance with national personal data protection regulations (KVKK).
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Harran University